Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting

被引：0
|
作者：
B. Muresan
C. Mamolo
J. C. Cappelleri
M. J. Postma
B. Heeg
机构：
[1] Ingress-health Netherlands,Department of Health Sciences, University Medical Center Groningen
[2] Pfizer Inc,Department of Economics, Econometrics and Finance, Faculty of Economics and Business
[3] University of Groningen,undefined
[4] University of Groningen,undefined
来源：
Applied Health Economics and Health Policy | 2021年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：929 / 940
页数：11
相关论文
共 50 条
  • [31] Cost-effectiveness of imatinib (GLEEVEC) as first-line treatment in chronic myeloid leukemia (CML)
    El Quagari, K
    Talbot, W
    Baladi, JF
    VALUE IN HEALTH, 2004, 7 (06) : 669 - 669
  • [32] Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia
    Poe-Hirr Hsyu
    Diane R. Mould
    Richard N. Upton
    Michael Amantea
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 209 - 218
  • [33] Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.
    Gambacorti-Passerini, Carlo
    Brummendorf, Tim H.
    Kim, Dong-Wook
    Goh, Yeow Tee
    Dyagil, Irina S.
    Pagnano, Katia
    Batai, Arpad
    Turkina, Anna G.
    Leip, Eric
    Purcell, Simon
    Leone, Jocelyn M.
    Viqueira, Andrea
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
    Gambacorti-Passerini, Carlo
    Cortes, Jorge E.
    Lipton, Jeff H.
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Crescenzo, Rocco
    Bardy-Bouxin, Nathalie
    Shapiro, Mark
    Noonan, Kay
    Leip, Eric
    DeAnnuntis, Liza
    Bruemmendorf, Tim H.
    Khoury, H. Jean
    HAEMATOLOGICA, 2018, 103 (08) : 1298 - 1307
  • [35] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Maino, E.
    Calistri, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Medeot, M.
    Ambrosetti, A.
    Semenzato, G.
    Fanin, R.
    HAEMATOLOGICA, 2015, 100 : 132 - 132
  • [36] Cost-effectiveness of interferon-α for chronic myeloid leukemia
    Goldman, JM
    ANNALS OF ONCOLOGY, 1998, 9 (04) : 351 - 352
  • [37] Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy
    Lucioni, Carlo
    Iannazzo, Sergio
    Mazzi, Silvio
    Saporiti, Giorgia
    Chiroli, Silvia
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (01) : 1 - 16
  • [38] Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients:: a national cohort study in Peru
    Suárez, PG
    Floyd, K
    Portocarrero, J
    Alarcón, E
    Rapiti, E
    Ramos, G
    Bonilla, C
    Sabogal, I
    Aranda, E
    Dye, C
    Raviglione, M
    Espinal, MA
    LANCET, 2002, 359 (9322): : 1980 - 1989
  • [39] The role of bosutinib in the treatment of chronic myeloid leukemia
    Gambacorti-Passerini, Carlo
    le Coutre, Philipp
    Piazza, Rocco
    FUTURE ONCOLOGY, 2020, 16 (02) : 4395 - 4408
  • [40] Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy
    Iurlo, Alessandra
    Bucelli, Cristina
    Intermesoli, Tamara
    Elena, Chiara
    D'Adda, Mariella
    Agostani, Elena
    Fiamenghi, Cristina
    Maffioli, Margherita
    Orofino, Nicola
    Lunghi, Francesca
    Gardellini, Angelo
    Carraro, Maria Cristina
    Inzoli, Alessandro
    Gigli, Federica
    Palazzolo, Roberto
    Bertolli, Vanda
    Cattaneo, Daniele
    Pungolino, Ester Maria
    Gambacorti-Passerini, Carlo
    ACTA HAEMATOLOGICA, 2024,
12345